特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
951624

体外診断の世界市場 (2020-2030年):競合環境・市場分析・成長予測

Global In Vitro Diagnostic Market: Focus on Product, Test Type, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 287 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
体外診断の世界市場 (2020-2030年):競合環境・市場分析・成長予測
出版日: 2020年07月30日
発行: BIS Research Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
担当者のコメント
2020年7月出版の「体外診断の世界市場」は、体外診断関係の消耗品、キット、試薬、ステントの市場分析を提供します。糖尿病、感染病、等々の病理別という角度でも市場を説明します。ご希望がございましたら、是非とも抜粋サンプルのご依頼を頂ければ幸いでございます。
  • 全表示
  • 概要
  • 目次
概要

世界の体外診断の市場は予測期間中5.06%のCAGRで推移し、2030年には1138億6000万米ドルの規模に成長すると予測されています。急速な低侵襲・非侵襲診断ツール&技術の採用率の上昇、世界的な老齢人口の増加、感染症・慢性疾患患者数の増加、医療費の増加、POC検査への需要の拡大などの要因が同市場の成長を推進しています。

当レポートでは、世界の体外診断の市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、法規制・償還シナリオ、市場規模の推移・予測、製品・検査タイプ・用途・エンドユーザー・地域/主要国など各種区分別の内訳、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

  • イントロダクション
  • 世界のIVD市場の展望
  • 償還シナリオ
  • 規制シナリオ
  • 市場規模と成長の可能性

第5章 COVID-19:IVD市場への影響

第6章 市場力学

  • 市場成長要因
  • 市場の抑制要因
  • 市場機会

第7章 市場分析・予測:製品別

  • 概要
  • 機器
  • 消耗品
    • キット
    • 試薬
  • ソフトウェア

第8章 市場分析・予測:テストタイプ別

  • 概要
  • イムノアッセイ
  • 臨床化学
  • 全血グルコースモニタリング
  • 分子診断
  • 微生物
  • 解剖病理
  • 血液
  • 凝固
  • 救命救急
  • 尿検査
  • その他

第9章 市場分析・予測:用途別

  • 概要
  • 糖尿病
  • 感染症
  • 腫瘍・癌
  • 循環器
  • 腎臓
  • 自己免疫疾患
  • 薬物検査・薬理ゲノミクス
  • HIV・エイズ
  • 女性の健康
  • その他

第10章 市場分析・予測:エンドユーザー別

  • 概要
  • 病院
  • 中央研究所
  • ポイントオブケア(POC)
  • クリニック
  • 学術機関
  • その他

第11章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • その他の地域

第12章 戦略的推奨事項

第13章 競合情勢

  • 主な戦略・展開
  • 市場シェア分析

第14章 企業プロファイル

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • Qiagen N.V.
  • Abbott Laboratories, Inc.
  • Thermo Fisher Scientific
  • Danaher Corporation
  • Myriad Genetics, Inc.
  • Laboratory Corporation of America Holdings
  • Siemens Healthineers, Inc.
  • Quest Diagnostics Incorporated
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • Biomerieux SA
  • Becton, Dickinson and Company
  • Ortho Clinical Diagnostics
  • Hologic, Inc.
  • DiaSorin S.p.A
  • Transasia Bio-Medicals Ltd.
目次
Product Code: BHL0946SA

Global In Vitro Diagnostic Market to Reach $113.86 Billion by 2030

Market Report Coverage - In Vitro Diagnostic

Market Segmentation

  • Product - Instruments, Consumables, and Software
  • Test Type - Immunoassay, Clinical Chemistry, Whole Blood Glucose Monitoring, Molecular Diagnostics, Microbiology, Anatomic Pathology, Hematology, Coagulation, Critical Care, Urinalysis, and Others
  • Application- Diabetes, Infectious Disease, Oncology/Cancer, Cardiology, Nephrology, Autoimmune Disease, Drug Testing/Pharmacogenomics, HIV/AIDS, Women Health, and Others
  • End User - Hospitals, Central Laboratories, Point-of-Care (POC), Clinics, Academic Institutions, and Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
  • Asia-Pacific - Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Middle East - Saudi Arabia, Israel, and Rest-of-Middle East
  • Rest-of-the-World

Growth Drivers

  • Rise in Adoption of Rapid, Minimally Invasive and Non-Invasive Diagnostics Tools & Techniques
  • Rise in the Global Geriatric Population
  • High Number of Patients with Infectious and Chronic Diseases
  • Rise in the Global Healthcare Expenditure
  • Rise in the Demand for POC Testing

Market Challenges

  • Uneven Reimbursement Scenario
  • Uncertain Regulatory Environment

Market Opportunities

  • Rise in the Demand for Molecular Diagnostics
  • Epigenomics Based Approach

Key Companies Profiled

Agilent Technologies, Inc., F. Hoffmann-La Roche, Illumina, Inc., Qiagen N.V., Abbott Laboratories, Inc., Thermo Fisher Scientific, Danaher Corporation, Myriad Genetics, Inc., Laboratory Corporation of America Holdings, Siemens Healthineers, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., Sysmex Corporation, bioMerieux S.A. Becton, Dickinson and Company, Ortho Clinical Diagnostics, Hologic, Inc, and DiaSorin S.p.A.

Key Questions Answered in this Report:

  • What are IVD solutions? How have different IVD solutions evolved over the years?
  • What are the major market drivers, challenges, and opportunities in the global IVD market?
  • What was the global IVD market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the market size expected to be in 2030?
  • How is each segment of the global IVD market expected to grow during the forecast period between 2020 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the IVD market in each region, namely, North America, Europe, Asia-Pacific, Latin America, Middle East, and Rest-of-the-World?
  • Which product among the two (assays and kits & instrument) are offered by key players such as Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?
  • Which test type is leading the market in 2019 and expected to dominate the market in 2030, and why?
  • Which application and end user type are leading the market in 2019 and are expected to dominate the market in 2030, and why?
  • Which region dominated the global IVD market in 2019, and what are the expected trends from each of the regions during the forecast period 2020-2030?
  • What are the emerging trends in the global in vitro diagnostic market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Healthcare experts have found IVD industry to be one of the most rapidly evolving markets and the global market for IVD is predicted to grow at a CAGR of 5.06% over the forecast period of 2020-2030. The market is driven by certain factors, which include rise in adoption of rapid, minimally invasive and non-invasive diagnostics tools & techniques, rise in the global geriatric population, high number of patients with infectious and chronic diseases, rise in the global healthcare expenditure, and rise in the demand for POC testing.

The market is favored by the development of rapid diagnostic instruments and consumables for several clinical areas, such as infectious disease, oncology/cancer, cardiology, HIV/AIDS, and nephrology, among others. Additionally, recent infectious disease outbreaks, such as COVID-19, have further propelled the growth of the global market.

Within the research report, the market is segmented on the basis of product, test type, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of IVD to increase the accuracy and to ensure shorter turn-around time for disease diagnosis. Due to the diverse product portfolio and intense market penetration, F. Hoffmann-La Roche has been a pioneer in this field and has been a significant competitor in this market.

On the basis of region, North America holds the largest share of the global in vitro diagnostic market due to growing incidence of infectious disease and cancer, including its various types, increased focus on democratizing precision diagnostics for various applications, increasing geriatric population, and favorable government reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global IVD Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary data sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Global IVD Market Outlook
    • 4.2.1 Global Diagnostic Expenditures
    • 4.2.2 Pricing Patterns for Diagnostics (IVD)
  • 4.3 Reimbursement Scenario
    • 4.3.1 U.S.
    • 4.3.2 Europe
  • 4.4 Regulatory Scenario
    • 4.4.1 U.S.
    • 4.4.2 Europe
    • 4.4.3 Asia-Pacific
    • 4.4.4 Latin America
  • 4.5 Market Size and Growth Potential
    • 4.5.1 Short Term Impact (2020-2025)
    • 4.5.2 Long Term Impact (2026-2030)

5 COVID-19: Impact on the IVD Market

  • 5.1 Situation Analysis
  • 5.2 Impact of COVID-19 on IVD Testing

6 Market Dynamics

  • 6.1 Market Drivers
    • 6.1.1 Rise in Adoption of Rapid, Minimally Invasive and Non-Invasive Diagnostics Tools & Techniques
    • 6.1.2 Rise in the Global Geriatric Population
    • 6.1.3 High Number of Patients with Infectious and Chronic Diseases
    • 6.1.4 Rise in the Global Healthcare Expenditure
    • 6.1.5 Rise in the Demand for POC Testing
  • 6.2 Market Restraints
    • 6.2.1 Uneven Reimbursement Scenario
    • 6.2.2 Uncertain Regulatory Environment
  • 6.3 Market Opportunities
    • 6.3.1 Rise in the Demand for Molecular Diagnostics
    • 6.3.2 Epigenomics-Based Approach

7 Global In-Vitro Diagnostics (IVD) Market (by Product)

  • 7.1 Overview
  • 7.2 Instruments
  • 7.3 Consumables
    • 7.3.1 Kits
    • 7.3.2 Reagents
  • 7.4 Software

8 Global In-Vitro Diagnostics (IVD) Market (by Test Type)

  • 8.1 Overview
  • 8.2 Immunoassay
  • 8.3 Clinical Chemistry
  • 8.4 Whole Blood Glucose Monitoring
  • 8.5 Molecular Diagnostics
  • 8.6 Microbiology
  • 8.7 Anatomic Pathology
  • 8.8 Hematology
  • 8.9 Coagulation
  • 8.1 Critical Care
  • 8.11 Urinalysis
  • 8.12 Others

9 Global In-Vitro Diagnostics (IVD) Market (by Application)

  • 9.1 Overview
  • 9.2 Diabetes
  • 9.3 Infectious Disease
  • 9.4 Oncology/Cancer
  • 9.5 Cardiology
  • 9.6 Nephrology
  • 9.7 Autoimmune Disease
  • 9.8 Drug Testing/Pharmacogenomics
  • 9.9 HIV/AIDS
  • 9.1 Women's Health
  • 9.11 Other Applications

10 Global In-Vitro Diagnostics (IVD) Market (by End User)

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Central Laboratories
  • 10.4 Point-of-Care (POC)
  • 10.5 Clinics
  • 10.6 Academic Institutions
  • 10.7 Other End Users

11 Global In-Vitro Diagnostics (IVD) Market (Region)

  • 11.1 North America
    • 11.1.1 North America IVD Market (by Test Type)
    • 11.1.2 U.S.
    • 11.1.3 Canada
  • 11.2 Europe
    • 11.2.1 Europe IVD Market (by Test Type)
    • 11.2.2 Germany
    • 11.2.3 U.K.
    • 11.2.4 France
    • 11.2.5 Italy
    • 11.2.6 Spain
    • 11.2.7 Netherlands
    • 11.2.8 Rest-of-Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Asia-Pacific IVD Market (by Test Type)
    • 11.3.2 Japan
    • 11.3.3 China
    • 11.3.4 India
    • 11.3.5 South Korea
    • 11.3.6 Australia
    • 11.3.7 Rest-of-Asia-Pacific
  • 11.4 Latin America
    • 11.4.1 LATAM IVD Market (by Test Type)
    • 11.4.2 Brazil
    • 11.4.3 Mexico
    • 11.4.4 Rest-of-Latin-America
  • 11.5 Middle East
    • 11.5.1 Middle East IVD Market (by Test Type)
    • 11.5.2 Saudi Arabia
    • 11.5.3 Israel
    • 11.5.4 Rest-of-Middle East
  • 11.6 Rest-of-the-World
    • 11.6.1 RoW IVD Market (by Test Type)

12 Strategic Recommendations

  • 12.1 Key Takeaways
  • 12.2 Gap Analysis
  • 12.3 Key Factors Influencing Decision Making in the IVD Market
  • 12.4 Technology Preferences

13 Competitive Landscape

  • 13.1 Key Strategies and Development
    • 13.1.1 Product Launch and Enhancements
    • 13.1.2 Approvals
    • 13.1.3 Synergistic Activities
    • 13.1.4 Acquisitions
    • 13.1.5 Expansions
  • 13.2 Market Share Analysis
  • 13.3 Growth Share Analysis (Opportunity Mapping)

14 Company Profiles

  • 14.1 Overview
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global IVD Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 F. Hoffmann-La Roche
    • 14.3.1 Company Overview
    • 14.3.2 Role of F. Hoffmann-La Roche AG in the Global IVD Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 Illumina, Inc.
    • 14.4.1 Company Overview
    • 14.4.2 Role of Illumina, Inc. in the Global IVD Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 Qiagen N.V.
    • 14.5.1 Company Overview
    • 14.5.2 Role of QIAGEN N.V. plc in the Global IVD Market
    • 14.5.3 Financials
    • 14.5.4 Key Insights About Financial Health of the Company
    • 14.5.5 SWOT Analysis
  • 14.6 Abbott Laboratories, Inc.
    • 14.6.1 Company Overview
    • 14.6.2 Role of Abbott Laboratories in the Global IVD Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Thermo Fisher Scientific
    • 14.7.1 Company Overview
    • 14.7.2 Role of Thermo Fisher Scientific in the Global IVD Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 Danaher Corporation
    • 14.8.1 Company Overview
    • 14.8.2 Role of Danaher Corporation in the Global IVD Market
    • 14.8.3 Financials
    • 14.8.4 Key Insights About Financial Health of the Company
    • 14.8.5 SWOT Analysis
  • 14.9 Myriad Genetics, Inc.
    • 14.9.1 Company Overview
    • 14.9.2 Role of Myriad Genetics, Inc. in the Global IVD Market
    • 14.9.3 Financials
    • 14.9.4 Key Insights About Financial Health of the Company
    • 14.9.5 SWOT Analysis
  • 14.1 Laboratory Corporation of America Holdings
    • 14.10.1 Company Overview
    • 14.10.2 Role of Laboratory Corporation of America Holdings in the Global IVD Market
    • 14.10.3 Financials
    • 14.10.4 SWOT Analysis
  • 14.11 Siemens Healthineers, Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of Siemens Healthineers, Inc. in the Global IVD Market
    • 14.11.3 Financials
    • 14.11.4 Key Insights About Financial Health of the Company
    • 14.11.5 SWOT Analysis
  • 14.12 Quest Diagnostics Incorporated
    • 14.12.1 Company Overview
    • 14.12.2 Role of Quest Diagnostics Incorporated in the Global IVD Market
    • 14.12.3 Financials
    • 14.12.4 SWOT Analysis
  • 14.13 Bio-Rad Laboratories, Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of Bio-Rad Laboratories, Inc. in the Global IVD Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Sysmex Corporation
    • 14.14.1 Company Overview
    • 14.14.2 Role of Sysmex Corporation in the Global IVD Market
    • 14.14.3 Financials
    • 14.14.4 Key Insights About Financial Health of the Company
    • 14.14.5 SWOT Analysis
  • 14.15 Biomerieux SA
    • 14.15.1 Company Overview
    • 14.15.2 Role of bioMerieux S.A. in the Global IVD Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights About Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Becton, Dickinson and Company
    • 14.16.1 Company Overview
    • 14.16.2 Role of Becton, Dickinson and Company in the Global IVD Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis
  • 14.17 Ortho Clinical Diagnostics
    • 14.17.1 Company Overview
    • 14.17.2 Role of Ortho Clinical Diagnostics in the Global IVD Market
    • 14.17.3 SWOT Analysis
  • 14.18 Hologic, Inc.
    • 14.18.1 Company Overview
    • 14.18.2 Role of Hologic, Inc. in the Global IVD Market
    • 14.18.3 Financials
    • 14.18.4 Key Insights About Financial Health of the Company
    • 14.18.5 SWOT Analysis
  • 14.19 DiaSorin S.p.A
    • 14.19.1 Company Overview
    • 14.19.2 Role of DiaSorin S.p.A. in the Global IVD Market
    • 14.19.3 Financials
    • 14.19.4 Key Insights About Financial Health of the Company
    • 14.19.5 SWOT Analysis
  • 14.2 Transasia Bio-Medicals Ltd.
    • 14.20.1 Company Overview
    • 14.20.2 Role of Transasia Bio-Medicals Ltd. in the Global IVD Market
    • 14.20.3 SWOT Analysis

List of Tables

  • Table 4.1: European Medical Device and IVD Payment Schemes
  • Table 5.1: COVID-19 Related Product Offering by Major Players
  • Table 5.2: Impact of COVID-19 on Different Countries
  • Table 7.1: Key Automated IVD Instruments
  • Table 8.1: Key IVD Immunoassay Solutions
  • Table 8.2: Key IVD Clinical Chemistry Solutions
  • Table 8.3: Key IVD Whole Blood Glucose Monitoring Solutions
  • Table 11.1: North America IVD Market (by Test Type), $Million, 2019-2030
  • Table 11.2: Europe IVD Market (by Test Type), $Million, 2019-2030
  • Table 11.3: Asia-Pacific IVD Market (by Test Type), $Million, 2019-2030
  • Table 11.4: LATAM IVD Market (by Test Type), $Million, 2019-2030
  • Table 11.5: Middle East IVD Market (by Test Type), $Million, 2019-2030
  • Table 11.6: RoW IVD Market (by Test Type), $Million, 2019-2030
  • Table 12.1: Major Issues in Research Laboratories in the Asia-Pacific Region

List of Figures

  • Figure 1: Impact Analysis on the Global IVD Market
  • Figure 2: Global IVD Market (by Product), $Million, 2020 vs. 2030
  • Figure 3: Global IVD Market (by Test Type), $Million, 2020 vs. 2030
  • Figure 4: Global IVD Market (by Application), $Million, 2020 vs. 2030
  • Figure 5: Global IVD Market (by End User), $Million, 2020 vs. 2030
  • Figure 6: Global IVD Market Snapshot (by Region)
  • Figure 2.1: Global IVD Market Segmentation
  • Figure 3.1: Global IVD Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.4: Bottom-up Approach (Segment-Wise Analysis)
  • Figure 4.1: Global IVD Market, 2019-2030
  • Figure 5.1: Global IVD Market, Pre- vs. Post-COVID-19
  • Figure 6.1: Global IVD Market: Market Dynamics
  • Figure 7.1: Global IVD Market, (by Product), $Million, 2020 vs. 2030
  • Figure 7.2: IVD Instrument Market, $Million, 2019-2030
  • Figure 7.3: IVD Consumables Market, $Million, 2019-2030
  • Figure 7.4: IVD Kits Market, $Million, 2019-2030
  • Figure 7.5: IVD Reagents Market, $Million, 2019-2030
  • Figure 7.6: IVD Software Market, $Million, 2019-2030
  • Figure 8.1: Global IVD Market (by Test Type), $Million, 2020 vs. 2030
  • Figure 8.2: IVD Immunoassay Market, $Million, 2019-2030
  • Figure 8.3: IVD Clinical Chemistry Market, $Million, 2019-2030
  • Figure 8.4: IVD Whole Blood Glucose Monitoring Market, $Million, 2019-2030
  • Figure 8.5: IVD Molecular Diagnostics Market, $Million, 2019-2030
  • Figure 8.6: IVD Microbiology Market, $Million, 2019-2030
  • Figure 8.7: IVD Anatomic Pathology Market, $Million, 2019-2030
  • Figure 8.8: IVD Hematology Market, $Million, 2019-2030
  • Figure 8.9: IVD Coagulation Market, $Million, 2019-2030
  • Figure 8.10: IVD Critical Care Market, $Million, 2019-2030
  • Figure 8.11: IVD Urinalysis Market, $Million, 2019-2030
  • Figure 8.12: IVD Other Test Type Market, $Million, 2019-2030
  • Figure 9.1: Global IVD Market (by Application), $Million, 2020 vs. 2030
  • Figure 9.2: IVD Market for Diabetes, $Million, 2019-2030
  • Figure 9.3: IVD Market for Infectious Disease, $Million, 2019-2030
  • Figure 9.4: IVD Market for Oncology/Cancer, $Million, 2019-2030
  • Figure 9.5: IVD Market for Cardiology, $Million, 2019-2030
  • Figure 9.6: IVD Market for Nephrology, $Million, 2019-2030
  • Figure 9.7: IVD Market for Autoimmune Disease, $Million, 2019-2030
  • Figure 9.8: IVD Market for Drug Testing/Pharmacogenomics, $Million, 2019-2030
  • Figure 9.9: IVD Market for HIV/AIDS, $Million, 2019-2030
  • Figure 9.10: IVD Market for Women Health, $Million, 2019-2030
  • Figure 9.11: IVD Market for Other Applications, $Million, 2019-2030
  • Figure 10.1: Global IVD Market (by End User), $Million, 2020 vs. 2030
  • Figure 10.2: IVD Market for Hospitals, $Million, 2019-2030
  • Figure 10.3: IVD Market for Central Laboratories, $Million, 2019-2030
  • Figure 10.4: IVD Market for POC, $Million, 2019-2030
  • Figure 10.5: IVD Market for Clinics, $Million, 2019-2030
  • Figure 10.6: IVD Market for Academic Institutions, $Million, 2019-2030
  • Figure 10.7: IVD Market for Other End Users, $Million, 2019-2030
  • Figure 11.1: Global IVD Market, $Million, 2019-2030
  • Figure 11.2: North America: Market Dynamics
  • Figure 11.3: North America IVD Market, $Million, 2019-2030
  • Figure 11.4: North America IVD Market (by Country), $Million, 2020 vs. 2030
  • Figure 11.5: U.S. IVD Market, $Million, 2019-2030
  • Figure 11.6: Canada IVD Market, $Million, 2019-2030
  • Figure 11.7: Europe: Market Dynamics
  • Figure 11.8: Europe IVD Market, $Million, 2019-2030
  • Figure 11.9: Europe IVD Market (by Country), $Million, 2020 vs. 2030
  • Figure 11.10: Germany IVD Market, $Million, 2019-2030
  • Figure 11.11: U.K. IVD Market, $Million, 2019-2030
  • Figure 11.12: France IVD Market, $Million, 2019-2030
  • Figure 11.13: Italy IVD Market, $Million, 2019-2030
  • Figure 11.14: Spain IVD Market, $Million, 2019-2030
  • Figure 11.15: Netherlands IVD Market, $Million, 2019-2030
  • Figure 11.16: Rest-of-Europe IVD Market, $Million, 2019-2030
  • Figure 11.17: Asia-Pacific: Market Dynamics
  • Figure 11.18: Asia-Pacific IVD Market, $Million, 2019-2030
  • Figure 11.19: Europe IVD Market (by Country), $Million, 2020 vs. 2030
  • Figure 11.20: Japan IVD Market, $Million, 2019-2030
  • Figure 11.21: China IVD Market, $Million, 2019-2030
  • Figure 11.22: India IVD Market, $Million, 2019-2030
  • Figure 11.23: South Korea IVD Market, $Million, 2019-2030
  • Figure 11.24: Australia IVD Market, $Million, 2019-2030
  • Figure 11.25: Rest-of-APAC IVD Market, $Million, 2019-2030
  • Figure 11.26: Latin America: Market Dynamics
  • Figure 11.27: Latin America IVD Market, $Million, 2019-2030
  • Figure 11.28: Latin America IVD Market (by Country), $Million, 2020 vs. 2030
  • Figure 11.29: Brazil IVD Market, $Million, 2019-2030
  • Figure 11.30: Mexico IVD Market, $Million, 2019-2030
  • Figure 11.31: Rest-of-Latin America IVD Market, $Million, 2019-2030
  • Figure 11.32: Middle East: Market Dynamics
  • Figure 11.33: Middle East IVD Market, $Million, 2019-2030
  • Figure 11.34: Middle East IVD Market (by Country), $Million, 2020 vs. 2030
  • Figure 11.35: Saudi Arabia IVD Market, $Million, 2019-2030
  • Figure 11.36: Israel IVD Market, $Million, 2019-2030
  • Figure 11.37: Rest-of-Middle East IVD Market, $Million, 2019-2030
  • Figure 11.38: Rest of the World IVD Market, $Million, 2019-2030
  • Figure 13.1: Share of Key Developments and Strategies, January 2017-April 2020
  • Figure 13.2: Product Launches and Enhancements Share (by Company), January 2017-April 2020
  • Figure 13.3: Approvals Share (by Company), January 2017-April 2020
  • Figure 13.4: Synergistic Activities Share (by Company), January 2017-April 2020
  • Figure 13.5: Acquisition and Merger Share (by Company), January 2017-April 2020
  • Figure 13.6: Market Share Analysis for the Global IVD Market, 2019
  • Figure 13.7: Growth Share Matrix for Global IVD Market (by Company)
  • Figure 14.1: Agilent Technologies, Inc.: Key Product Portfolio
  • Figure 14.2: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 14.3: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.4: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.5: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.6: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.7: F. Hoffmann-La Roche AG: Key Product Portfolio
  • Figure 14.8: F. Hoffmann-La Roche AG: Overall Financials, 2017-2019
  • Figure 14.9: F. Hoffmann-La Roche AG: Revenue (by Segment), $Million, 2017-2019
  • Figure 14.10: F. Hoffmann-La Roche AG: Revenue (by Region), 2017-2019
  • Figure 14.11: F. Hoffmann-La Roche AG: R&D Expenditure, 2017-2019
  • Figure 14.12: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 14.13: Illumina, Inc.: Key Product Portfolio
  • Figure 14.14: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 14.15: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.16: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.17: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.18: Illumina, Inc.: SWOT Analysis
  • Figure 14.19: QIAGEN N.V.: Key Product Portfolio
  • Figure 14.20: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 14.21: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 14.22: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 14.23: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 14.24: QIAGEN N.V.: SWOT Analysis
  • Figure 14.25: Abbott Laboratories: Key Product Offerings
  • Figure 14.26: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 14.27: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 14.28: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
  • Figure 14.29: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 14.30: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 14.31: Abbott Laboratories: SWOT Analysis
  • Figure 14.32: Thermo Fisher Scientific Inc.: Key Product Offerings
  • Figure 14.33: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 14.34: Thermo Fisher Scientific Inc: Sales (by Segment), 2017-2019
  • Figure 14.35: Thermo Fisher Scientific Inc.: Sales (by Region), 2017-2019
  • Figure 14.36: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 14.37: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 14.38: Danaher Corporation: Product Portfolio
  • Figure 14.39: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 14.40: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 14.41: Danaher Corporation: Revenue (by Region), 2017-2019
  • Figure 14.42: Danaher Corporation: R&D Expenditure, 2017-2019
  • Figure 14.43: Danaher Corporation: SWOT Analysis
  • Figure 14.44: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 14.45: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 14.46: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
  • Figure 14.47: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.48: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 14.49: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 14.50: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 14.51: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 14.52: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
  • Figure 14.53: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 14.54: Siemens Healthineers, Inc.: Overall Product Portfolio
  • Figure 14.55: Siemens Healthineers, Inc.: Overall Financials, 2017-2019
  • Figure 14.56: Siemens Healthineers, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.57: Siemens Healthineers, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.58: Siemens Healthineers, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.59: Siemens Healthineers, Inc.: SWOT Analysis
  • Figure 14.60: Quest Diagnostics Incorporated: Overall Product Portfolio
  • Figure 14.61: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 14.62: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 14.63: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 14.64: Bio-Rad Laboratories, Inc.: Key Product Portfolio
  • Figure 14.65: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 14.66: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.67: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.68: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.69: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 14.70: Sysmex Corporation: Overall Product Portfolio
  • Figure 14.71: Sysmex Corporation: Overall Financials, 2017-2019
  • Figure 14.72: Sysmex Corporation: Sales (by Segment), 2017-2019
  • Figure 14.73: Sysmex Corporation: Sales (by Region), 2017-2019
  • Figure 14.74: Sysmex Corporation: R&D Expenditure, 2017-2019
  • Figure 14.75: Sysmex Corporation: SWOT Analysis
  • Figure 14.76: bioMerieux S.A.: Overall Product Portfolio
  • Figure 14.77: bioMerieux S.A.: Overall Financials, 2017-2019
  • Figure 14.78: bioMerieux S.A.: Revenue (by Segment), 2017-2019
  • Figure 14.79: bioMerieux S.A.: Revenue (by Region), 2017-2019
  • Figure 14.80: bioMerieux S.A.: R&D Expenditure, 2017-2019
  • Figure 14.81: bioMerieux S.A.: SWOT Analysis
  • Figure 14.82: Beckton, Dickinson and Company: Overall Product Portfolio
  • Figure 14.83: Becton, Dickinson and Company: Overall Financials, 2017-2019
  • Figure 14.84: Becton, Dickinson and Company: Revenue (by Business Segment), 2017-2019
  • Figure 14.85: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
  • Figure 14.86: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
  • Figure 14.87: Becton, Dickinson and Company: SWOT Analysis
  • Figure 14.88: Ortho Clinical Diagnostics: Overall Product Portfolio
  • Figure 14.89: Ortho Clinical Diagnostics: SWOT Analysis
  • Figure 14.90: Hologic, Inc.: Overall Product Portfolio
  • Figure 14.91: Hologic, Inc.: Overall Financials, 2017-2019
  • Figure 14.92: Hologic, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.93: Hologic, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.94: Hologic, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.95: Hologic, Inc.: SWOT Analysis
  • Figure 14.96: DiaSorin S.p.A.: Overall Product Portfolio
  • Figure 14.97: DiaSorin S.p.A.: Overall Financials, 2017-2019
  • Figure 14.98: DiaSorin S.p.A.: Revenue (by Segment), 2017-2019
  • Figure 14.99: DiaSorin S.p.A.: by Region, 2017-2019
  • Figure 14.100: DiaSorin S.p.A: R&D Expenditure, 2017-2019
  • Figure 14.101: DiaSorin S.p.A: SWOT Analysis
  • Figure 14.102: Transasia Bio-Medicals Ltd.: Overall Product Portfolio
  • Figure 14.103: Transasia Bio-Medicals Ltd.: SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.